BACKGROUND AND PURPOSE: Carboxylesterases (CEs) metabolize a wide range of xenobiotic substrates including heroin, cocaine, meperidine and the anticancer agent CPT-11. In this study, we have purified to homogeneity human liver and intestinal CEs and compared their ability with hydrolyse heroin, cocaine and CPT-11. EXPERIMENTAL APPROACH: The hydrolysis of heroin and cocaine by recombinant human CEs was evaluated and the kinetic parameters determined. In addition, microsomal samples prepared from these tissues were subjected to chromatographic separation, and substrate hydrolysis and amounts of different CEs were determined. KEY RESULTS: In contrast to previous reports, cocaine was not hydrolysed by the human liver CE, hCE1 (CES1), either as highly active recombinant protein or as CEs isolated from human liver or intestinal extracts. These results correlated well with computer-assisted molecular modelling studies that suggested that hydrolysis of cocaine by hCE1 (CES1), would be unlikely to occur. However, cocaine, heroin and CPT-11 were all substrates for the intestinal CE, hiCE (CES2), as determined using both the recombinant protein and the tissue fractions. Again, these data were in agreement with the modelling results. CONCLUSIONS AND IMPLICATIONS: These results indicate that the human liver CE is unlikely to play a role in the metabolism of cocaine and that hydrolysis of this substrate by this class of enzymes is via the human intestinal protein hiCE (CES2). In addition, because no enzyme inhibition is observed at high cocaine concentrations, potentially this route of hydrolysis is important in individuals who overdose on this agent.
BACKGROUND AND PURPOSE:Carboxylesterases (CEs) metabolize a wide range of xenobiotic substrates including heroin, cocaine, meperidine and the anticancer agent CPT-11. In this study, we have purified to homogeneity human liver and intestinal CEs and compared their ability with hydrolyse heroin, cocaine and CPT-11. EXPERIMENTAL APPROACH: The hydrolysis of heroin and cocaine by recombinant human CEs was evaluated and the kinetic parameters determined. In addition, microsomal samples prepared from these tissues were subjected to chromatographic separation, and substrate hydrolysis and amounts of different CEs were determined. KEY RESULTS: In contrast to previous reports, cocaine was not hydrolysed by the human liver CE, hCE1 (CES1), either as highly active recombinant protein or as CEs isolated from human liver or intestinal extracts. These results correlated well with computer-assisted molecular modelling studies that suggested that hydrolysis of cocaine by hCE1 (CES1), would be unlikely to occur. However, cocaine, heroin and CPT-11 were all substrates for the intestinal CE, hiCE (CES2), as determined using both the recombinant protein and the tissue fractions. Again, these data were in agreement with the modelling results. CONCLUSIONS AND IMPLICATIONS: These results indicate that the human liver CE is unlikely to play a role in the metabolism of cocaine and that hydrolysis of this substrate by this class of enzymes is via the human intestinal protein hiCE (CES2). In addition, because no enzyme inhibition is observed at high cocaine concentrations, potentially this route of hydrolysis is important in individuals who overdose on this agent.
Authors: E V Pindel; N Y Kedishvili; T L Abraham; M R Brzezinski; J Zhang; R A Dean; W F Bosron Journal: J Biol Chem Date: 1997-06-06 Impact factor: 5.157
Authors: Christopher D Fleming; Sompop Bencharit; Carol C Edwards; Janice L Hyatt; Lyudmila Tsurkan; Feng Bai; Charles Fraga; Christopher L Morton; Escher L Howard-Williams; Philip M Potter; Matthew R Redinbo Journal: J Mol Biol Date: 2005-09-09 Impact factor: 5.469
Authors: Randy M Wadkins; Janice L Hyatt; Xin Wei; Kyoung Jin P Yoon; Monika Wierdl; Carol C Edwards; Christopher L Morton; John C Obenauer; Komath Damodaran; Paul Beroza; Mary K Danks; Philip M Potter Journal: J Med Chem Date: 2005-04-21 Impact factor: 7.446
Authors: Janice L Hyatt; Vanessa Stacy; Randy M Wadkins; Kyoung Jin P Yoon; Monika Wierdl; Carol C Edwards; Matthias Zeller; Allen D Hunter; Mary K Danks; Guy Crundwell; Philip M Potter Journal: J Med Chem Date: 2005-08-25 Impact factor: 7.446
Authors: Hao-Jie Zhu; Kennerly S Patrick; Hong-Jie Yuan; Jun-Sheng Wang; Jennifer L Donovan; C Lindsay DeVane; Robert Malcolm; Julie A Johnson; Geri L Youngblood; Douglas H Sweet; Taimour Y Langaee; John S Markowitz Journal: Am J Hum Genet Date: 2008-05-15 Impact factor: 11.025
Authors: François Girardin; Katharina M Rentsch; Marc-André Schwab; Marco Maggiorini; Christiane Pauli-Magnus; Gerd A Kullak-Ublick; Peter J Meier; Karin Fattinger Journal: Clin Pharmacol Ther Date: 2003-10 Impact factor: 6.875
Authors: Jenna A Rhoades; Yuri K Peterson; Hao-Jie Zhu; David I Appel; Charles A Peloquin; John S Markowitz Journal: Pharm Res Date: 2011-12-09 Impact factor: 4.200
Authors: Shuqi Xie; Abdolsamad Borazjani; M Jason Hatfield; Carol C Edwards; Philip M Potter; Matthew K Ross Journal: Chem Res Toxicol Date: 2010-12-20 Impact factor: 3.739
Authors: J Allen Crow; Victoria Bittles; Katye L Herring; Abdolsamad Borazjani; Philip M Potter; Matthew K Ross Journal: Toxicol Appl Pharmacol Date: 2011-11-04 Impact factor: 4.219
Authors: M Jason Hatfield; Randall J Binder; Rowan Gannon; Ellie M Fratt; John Bowling; Philip M Potter Journal: J Nat Prod Date: 2018-10-23 Impact factor: 4.050
Authors: M Jason Hatfield; Lyudmila G Tsurkan; Janice L Hyatt; Carol C Edwards; Andrew Lemoff; Cynthia Jeffries; Bing Yan; Philip M Potter Journal: J Nat Prod Date: 2013-01-03 Impact factor: 4.050